The Medicines and Healthcare products Regulatory Agency (MHRA) announced that from the 31st of January 2024 new regulatory measures have been implemented to ensure that the known harms associated with valproate use are reduced.
The UK regulator for medicines, medical devices and blood components for transfusion in the UK, The Medicines and Healthcare products Regulatory Agency (MHRA) have further extended the validity period of Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certificates.
If you have been keeping an eye on the news lately Donanemab will not be a new name to you. Donanemab is the latest break through drug for the treatment of Alzheimer’s.
Anyone who has recently reviewed the Medicines and Healthcare products Regulatory Agency (MHRA) CMS may have noticed the notification at the bottom of the search page regarding GMP and GDP Certificates, stating the following
On the 16th of November 2022 the Medicines and Healthcare products Regulatory Agency (MHRA) released a blog with guidance on the process for approving Manufacturing Authorisations/ API Registrations in relation to unlicensed Cannabis-Based Products for Medicinal (CBPM) use.
